Navigation Links
Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian

WASHINGTON, March 16 /PRNewswire-USNewswire/ -- American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today. The settlement resolves allegations that, between January 1, 2000 and December 29, 2008, Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug, which is used to treat chronic moderate to severe pain. Alpharma is now a wholly-owned subsidiary of Bristol, Tenn.-based King Pharmaceuticals Inc.

Under the agreement announced today, the proceeds from the settlement will be split between the federal government and various states, with the United States receiving roughly $33.6 million to resolve the federal claims and the states receiving approximately $8.9 million to settle their respective claims.

"Illegal marketing of pharmaceutical drugs jeopardizes the public's confidence in our health care system," said Tony West, Assistant Attorney General for the Civil Division of the Department of Justice. "All consumers have the right to know that their health care provider's judgment about drugs they should take has not been undermined by misinformation or kickbacks from pharmaceutical manufacturers."

The settlement resolves a lawsuit brought by a whistleblower, Debra Parks, in 2006 under the qui tam or whistleblower provisions of the False Claims Act, which permit private citizens with knowledge of fraud against the government to bring a lawsuit on behalf of the United States and to share in any recovery. Under the civil settlement announced today, Ms. Parks will receive $5.33 million out of the federal share of the recovery.

"Health care decisions must be based solely upon what is best for the individual patient and not on which pharmaceutical company is paying the doctor the biggest kickback," said Rod J. Rosenstein, U.S. Attorney for the District of Maryland.

Assistant Attorney General West and U.S. Attorney Rosenstein noted that today's settlement is the result of collaboration between the Justice Department's Civil Division and the U.S. Attorney's Office for the District of Maryland, with assistance from the National Association of Medicaid Fraud Control Units; the Department of Health and Human Services, Office of Inspector General; the Defense Criminal Investigative Service; the Office of Personnel Management, Office of Inspector General; and the Federal Bureau of Investigation.

This settlement is part of the government's emphasis on combating health care fraud. One of the most powerful tools in that effort is the False Claims Act, which the Justice Department has used to recover approximately $2.2 billion since January 2009 in cases involving fraud against federal health care programs. The Justice Department's total recoveries in False Claims Act cases since January 2009 have topped $3 billion.


SOURCE U.S. Department of Justice

Back to top



SOURCE U.S. Department of Justice
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
2. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
3. Globus Medical Raises $110 Million in Series E Financing Round
4. Atritech Announces Completion of a $22 Million Equity Financing
5. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
6. EntreMed Raises $20 Million to Support Clinical Development Program
7. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
10. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
(Date:11/30/2015)... November 30, 2015 --> ... "Dental Lasers Market by Product (Soft Tissue, All Tissue, Dental ... (Hospitals, Clinics), and Geography - Global Forecast to 2020", published ... 2020, at a CAGR of 5.2% during the forecast period ... data Tables and 62 Figures spread through 167 P ...
(Date:11/30/2015)... 2015  PTS Diagnostics, the U.S.-based manufacturer of point-of-care ... A1CNow ® systems, and PTS Detect™ cotinine systems, ... that will propel the company into the mHealth market. ... Europe . The technology is a system that ... smartphones and tablets, and uses test strip technology already ...
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... two new additions to its industry-leading suite of automated breast density assessment ... North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth #2377). ...
(Date:11/30/2015)... ... 2015 , ... Holcomb – Kreithen Plastic Surgery and ... in Florida, is proud to announce that Dr. Joshua Kreithen, one of its ... a Johnson & Johnson Company. , Ethicon is a global medical device company ...
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... the assets of DataTrade Solutions Inc., a Healthcare IT consulting, development and support ... the programming and technical experience available within DataTrade to extend the services currently ...
(Date:11/30/2015)... ... 2015 , ... GKhair & Tibolli team members and artists were excited and ... November 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. ... top of the line fashion journalists. The San Juan Beauty Show carries immense credibility ...
Breaking Medicine News(10 mins):